For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Ono Nets 16.8% Sales Growth on Opdivo, Forxiga; 400 Billion-Plus Yen Eyed for FY2022
May 12, 2022
- Asahi Kasei Sues Sawai over Manufacturing Method of Teribone Generic
May 11, 2022
- Kyowa Kirin’s Q1 Sales Up 8.2% on Robust Overseas Performance Driven by Crysvita
May 11, 2022
- Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
May 11, 2022
- Healios, NCC to Evaluate Antitumor Effects of eNK Cells
May 11, 2022
- Santen Snags China OK for Vernal Keratoconjunctivitis Drug
May 11, 2022
- Eisai Completes Rolling Submission for Lecanemab in US
May 11, 2022
- Eisai Sets to File Ultra-High Dose Mecobalamin for ALS in Japan
May 11, 2022
- RaQualia’s Acid Reducer Tegoprazan Now Available in China
May 10, 2022
- 1st Dose of COVID-19 Jab Given in Adult and Pediatric Trials: KM Biologics/Meiji
May 10, 2022
- Kyoto University’s BMS Building Breaks Ground for I/O Research with 5.5 Billion Yen Donation
May 10, 2022
- Argenx’s 1st Med in Japan Vyvgart Now Available for Generalized Myasthenia Gravis
May 10, 2022
- FDA Defers PDUFA Date for Myfembree for Endometriosis Use: Myovant/Pfizer
May 10, 2022
- Maruho Grabs Japan Rights for JAK2 Inhibitor Ruxolitinib Cream
May 9, 2022
- Sumitomo Pharma Grants Narcolepsy Drug Rights to Jazz
May 9, 2022
- Enhertu Gets Second-Line Breast Cancer Nod in US: Daiichi Sankyo/AZ
May 9, 2022
- Eisai Slashes FY2021 Profit Outlook on Aduhelm Woes
May 9, 2022
- BMS Begins New PI for Compound Derived from PeptiDream Platform
May 9, 2022
- Emgality Now Available for Self-Injection in Japan: Lilly/Daiichi Sankyo
May 9, 2022
- Relugolix Approved in Europe for Prostate Cancer
May 9, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…